Displaying One Session

Seagen - Navigating a new era in HER2+ metastatic breast cancer: Focus on HER2CLIMB  (ID 116)

Time
10:30 - 12:00

Charting the course of HER2-targeted therapies (ID 4720)

Base camp: HER2CLIMB study design and patient population (ID 4721)

Scaling HER2CLIMB key outcomes and predefined subgroups (ID 4722)

Traversing HER2CLIMB safety and quality of life (ID 4723)

Harnessing expert opinion: Live panel discussion and Q&A (ID 4724)